Please login to the form below

Not currently logged in
Email:
Password:

Aquapharm awarded GBP 4m funding

Scotland-headquartered Aquapharm Biodiscovery has raised GBP 4m (USD 8m) in funding from equity groups, which include the venture capital arm of Tate & Lyle and Dutch venture capital firm, Aescap.

Scotland-headquartered Aquapharm Biodiscovery has raised GBP 4m (USD 8m) in funding from equity groups, which include the venture capital arm of Tate & Lyle and Dutch venture capital firm, Aescap.

Aquapharm develops antiinfectives from microscopic marine elements and is also developing anti-ageing treatments through advanced fermentation technology.

Shareholders in the company include Scottish and Argyll and Islands Enterprise have also increased investment in Aquapharm.

The company has built up a library of over 6500 marine bacteria and fungi and is using the microorganisms to look for products, such as new antibiotics and "functional" foods with health-giving benefits, such as anti-oxidants.

Dr Simon Barnes, managing partner of Tate & Lyle Ventures, said that Aquapharm had an unrivalled ability to develop natural marine-derived ingredients for a wide range of functional food applications and nutraceuticals, in an interview with a local newspaper.

25th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics